Clinical Trials

27 enrolled 10 charts

Kidney Diseases, Kidney Neoplasms, Neoplasm Metastasis

NCT03260504 2025-12-08

Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Phase 1 Terminated

6 enrolled 11 charts

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT02926053 2024-11-22

TIL Therapy for Metastatic Renal Cell Carcinoma

Phase 1 Completed

5 enrolled 8 charts

Carcinoma, Renal Cell

NCT00554515 2024-08-28

SELECT

123 enrolled 22 charts

BreastDermatologicGenitourinaryGynecologic

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT02111850 2022-03-29

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

Phase 1/2 Completed

21 enrolled 22 charts

Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma

NCT00414765 2021-06-08

Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

Phase 4 Completed

26 enrolled 7 charts

Carcinoma, Renal Cell, Melanoma

NCT01550367 2020-01-02

Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)

Phase 1/2 Completed

30 enrolled 20 charts

Carcinoma, Renal Cell

NCT01218867 2019-12-10

CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

Phase 1/2 Terminated

24 enrolled 18 charts

Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT00670748 2019-11-19

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

45 enrolled 15 charts

BreastDermatologicGenitourinaryGynecologic

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis

NCT02153905 2019-06-17

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

Phase 1/2 Terminated

3 enrolled 14 charts

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT00853021 2019-06-05

Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney

26 enrolled 11 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00085436 2018-06-26

DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC

18 enrolled 8 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01585428 2018-03-07

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers

GastrointestinalGenitourinaryGynecologicHead & Neck

29 enrolled 12 charts

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Papillomavirus Infections

NCT02280811 2017-09-06

T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers

Phase 1/2 Completed

12 enrolled 19 charts

GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms

NCT00089778 2017-08-01

Vaccine Treatment of Kidney Cancer

11 enrolled 12 charts

Kidney Neoplasms

NCT00704938 2015-10-28

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

3 enrolled 8 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

NCT01160445 2015-10-28

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

9 enrolled 9 charts

Kidney Neoplasms, Melanoma

NCT01273181 2015-10-28

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

Phase 1/2 Terminated

9 enrolled 13 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT00126490 2015-06-30

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

19 enrolled 9 charts

Carcinoma, Renal Cell

NCT00328861 2012-11-05

Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer

8 enrolled 8 charts

Kidney Neoplasms, Melanoma

NCT00393029 2011-08-15

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

12 enrolled 10 charts